Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACUMIN: Minocycline PK in Critically-Ill Adults
NCT03369951Phase 4Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of minocycline in Gram-negative bacterial infection, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Area Under the Curve 0 to 24 Hours After a Dose, Area Under the Curve From 0 to Infinity at 48 hours and 7 more. Started Mar 2018; status: completed.
02
Drugs
minocycline
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT03369951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03369951.